Lates News

According to the AI Quick Report of Every Economy, Pacific released a research report on May 2, giving a buy rating to Ren Fu Medicine (600079.SH). The main reasons for the rating include: 1) The core subsidiary business continues to maintain steady growth; 2) Open a new strategic synergy journey with China Merchants Group. (Daily Economic News)